EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N. Kumar, DM, Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-CVD-05(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Cardiovascular Disorder is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Ischemic cardiomyopathy, chronic heart failure with reduced ejection fraction (HFrEF), and refractory angina cause progressive loss of viable cardiomyocytes, microvascular rarefaction, and adverse ventricular remodeling.
Biological Rationale & Paracrine Action:
Investigates the paracrine actions of clinical-grade umbilical cord mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to release angiogenic factors (VEGF, bFGF), downregulate myocardial fibrosis, and support microvascular perfusion alongside guideline-directed medical therapy (GDMT).
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Patients with chronic ischemic heart failure (NYHA Class II–III), prior myocardial infarction, or non-ischemic cardiomyopathy unresponsive to optimal medical therapy.
Mandatory Pre-Procedure Diagnostics:
Recent 2D-Echocardiogram (measuring baseline Left Ventricular Ejection Fraction / LVEF), Cardiac MRI (evaluating myocardial viability and scar burden), coronary angiography (verifying stable coronary anatomy), 24-hour Holter monitoring (screening for ventricular arrhythmias), and NT-proBNP levels.
Strict Safety Exclusion Parameters:
Refractory cardiogenic shock, sustained hemodynamically unstable ventricular tachycardia/fibrillation, critical uncorrected primary valve stenosis, severe pulmonary arterial hypertension, or active acute coronary syndrome.
Triage Protocol & Multi-Specialty Clearance:
Independent review by an interventional cardiologist and cardiothoracic surgeon before medical visa clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Ejection Fraction Support: Modest potential improvements or stabilization in Left Ventricular Ejection Fraction (LVEF) on follow-up echocardiography.
- Exercise Capacity: Increased 6-minute walk distance (6MWD) and functional tolerance for everyday physical exertion.
- Symptom Reduction: Decrease in angina frequency (CCS class) and subjective dyspnea (NYHA functional class).
- Neurohormonal Modulation: Favorable stabilization in serum NT-proBNP cardiac stress biomarkers.
Documented Procedural Risks & Limits:
- Transient post-infusion low-grade pyrexia or fatigue resolving within 24–48 hours.
- Rare catheterization-related risks (if intracoronary/transendocardial delivery is utilized): vascular access site hematoma, transient arrhythmias, or coronary dissection.
- No Guaranteed Tissue Regeneration: Stem cells cannot fully revive dense, transmural calcified scar tissue or guarantee complete reversal of end-stage heart failure.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Heart Centers
Procedures performed within dedicated cardiology institutes accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and JCI.
Advanced Hybrid Cath Labs
Access to high-resolution biplane digital fluoroscopy, intracardiac electroanatomic mapping (NOGA-guided delivery), and emergency surgical backup.
Multidisciplinary Oversight
Collaborative care led by senior clinical cardiologists, interventionalists, and intensive care intensivists.
Institutional Ethics Governance
Administered strictly under protocols approved by a CDSCO- and DHR-registered Institutional Ethics Committee (IEC).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with lead cardiologists to assess cardiac viability imaging and define realistic expectations.
Government Medical Visa
Fast-track assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation letters.
Dedicated Case Liaison
Multilingual coordinator managing airport transfers, daily schedule coordination, and medical document translation.
Structured Long-Term Follow-Up
Telehealth checkpoints at Months 1, 3, 6, and 12, coordinating repeat echocardiograms and Holter metrics directly with your local home cardiologist.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Monitored Airport Transfers
Private, air-conditioned vehicle transit equipped with emergency monitoring support to ensure low-stress travel.
Inpatient Living
Private telemetry-monitored hospital rooms with attendant beds, continuous cardiac vitals tracking, and 24/7 cardiac nursing care.
Outpatient Recovery Stays
Inspected partner serviced apartments within 10 minutes of the cardiac center with elevator access and low physical strain.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 6 days structured in-hospital cardiac observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Cardiovascular Disorder
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Large-Scale Phase 3 Trial of Mesenchymal Precursor Cells in HFrEF (DREAM-HF)
Perin, E. C., Borow, K. M., Henry, T. D., Mendelsohn, F. O., Miller, L. W., Swiggum, E., ... & DREAM-HF Investigators. (2023). Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure. Journal of the American College of Cardiology, 81(9), 849–863.
Transendocardial Autologous MSCs vs. Bone Marrow Mononuclear Cells (TAC-HFT Trial)
Heldman, A. W., DiFede, D. L., Fishman, J. E., Zambrano, J. P., Trachtenberg, B. H., Karantalis, V., Mushtaq, M., Williams, A. R., Suncion, V. Y., McNiece, I. K., Ghersin, E., Soto, V., Lopera, G., Miki, R., Willens, H., Hendel, R., Mitrani, R., Pattany, P., Feigenbaum, G., Oskouei, B., Byrnes, J., Yuan, S. C., Centeno, J., Pujol, M. V., Delgado, C., Lowery, M. H., Rouy, D., Altman, P., Foo, C. W., da Silva, J., Anderson, E., Kemper, R., & Hare, J. M. (2014). Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA, 311(1), 62–73.
Double-Blind Placebo-Controlled Trial of Umbilical Cord MSCs in HFrEF (RIMECARD Trial)
Bartolucci, J., Verdugo, F. J., González, P. L., Larrea, R. E., Abarzua, E., Goset, C., Rojo, P., Palma, I., Lamich, R., Pedreros, P. A., Valdivia, G., Lopez, V. M., Nazzal, C., Alcayaga-Miranda, F., Cuenca, J., Brobeck, M. J., Patel, A. N., Figueroa, F. E., & Khoury, M. (2017). Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial). Circulation Research, 121(10), 1192–1204.
Multicenter Indian Trial of Allogeneic Bone Marrow MSCs in Post-PCI Acute Ischemic Injury
Chullikana, A., Majumdar, A. S., Gottipamula, S., Krishnamurthy, S., Kumar, A. S., Prakash, V. S., & Gupta, P. K. (2015). Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy, 17(3), 250–261.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell therapy for cardiovascular diseases and heart failure is classified as investigational and experimental. It is not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. Patients must strictly continue their prescribed guideline-directed cardiovascular medications and never discontinue cardiac therapy without direct specialist guidance.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.